

David M Charytan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6078183/publications.pdf>

Version: 2024-02-01

113
papers

9,207
citations

101384

36
h-index

42291

92
g-index

115
all docs

115
docs citations

115
times ranked

10999
citing authors

#	ARTICLE	IF	CITATIONS
1	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.	13.9	3,760
2	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 845-854.	5.5	595
3	Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. <i>EClinicalMedicine</i> , 2020, 24, 100434.	3.2	465
4	Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.	1.2	403
5	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	2.6	260
6	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
7	AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 161-176.	3.0	207
8	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.	1.4	194
9	Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. <i>Intensive Care Medicine</i> , 2021, 47, 208-221.	3.9	143
10	Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. <i>Kidney International</i> , 2018, 93, 941-951.	2.6	139
11	Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2961-2970.	1.2	115
12	Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States. <i>American Journal of Kidney Diseases</i> , 2011, 58, 409-417.	2.1	110
13	In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. <i>BMJ</i> , 2020, 371, m3513.	3.0	108
14	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.	3.0	106
15	Early Angiography in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1032-1043.	2.2	103
16	Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 880-882.	2.2	101
17	Distribution of Coronary Artery Disease and Relation to Mortality in Asymptomatic Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2007, 49, 409-416.	2.1	95
18	Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. <i>International Journal of Cardiology</i> , 2014, 176, 99-109.	0.8	87

#	ARTICLE	IF	CITATIONS
19	Effects of Canagliflozin in Patients with Baseline eGFR $\leq 30\text{ ml/min per }1.73\text{ m}^2\text{. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1705-1714.}$	2.2	87
20	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1199-1208.	2.2	83
21	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2925-2936.	3.0	82
22	The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. <i>American Heart Journal</i> , 2006, 152, 558-564.	1.2	81
23	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	2.6	80
24	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	1.0	80
25	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 3442-3451.	1.0	78
26	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. <i>Kidney International</i> , 2019, 95, 973-982.	2.6	70
27	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1735-1749.	1.6	60
28	Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. <i>Kidney International</i> , 2018, 93, 501-509.	2.6	59
29	Risks of Death and End-Stage Renal Disease After Surgical Compared With Percutaneous Coronary Revascularization in Elderly Patients With Chronic Kidney Disease. <i>Circulation</i> , 2012, 126, S164-9.	1.6	58
30	Arrhythmia and Sudden Death in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 721-734.	2.2	57
31	Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment. <i>Circulation</i> , 2020, 141, 21-33.	1.6	54
32	A Decision-Making Algorithm for Initiation and Discontinuation of RRT in Severe AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 228-236.	2.2	52
33	Risks of coronary artery bypass surgery in dialysis-dependent patients—analysis of the 2001 National Inpatient Sample. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1665-1671.	0.4	49
34	Decreasing Incidence of Acute Kidney Injury in Patients with COVID-19 Critical Illness in New York City. <i>Kidney International Reports</i> , 2021, 6, 916-927.	0.4	45
35	Hospital-Level Variation in Death for Critically Ill Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 403-411.	2.5	39
36	Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. <i>American Journal of Kidney Diseases</i> , 2015, 66, 196-205.	2.1	38

#	ARTICLE	IF	CITATIONS
37	Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. <i>Kidney International</i> , 2016, 90, 411-421.	2.6	38
38	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.	2.2	37
39	Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2020-2030.	3.0	37
40	Kidney Function and Use of Recommended Medications after Myocardial Infarction in Elderly Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 796-801.	2.2	32
41	The axis of local cardiac endogenous Klotho-TGF- β 1-Wnt signaling mediates cardiac fibrosis in human. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 136, 113-124.	0.9	32
42	Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3034-3043.	3.0	30
43	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30
44	Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2015, 66, 429-440.	2.1	29
45	Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1624-1633.	2.2	29
46	Long-term Clinical Outcomes Following Drug-Eluting or Bare-Metal Stent Placement in Patients With Severely Reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. <i>American Journal of Kidney Diseases</i> , 2011, 57, 202-211.	2.1	28
47	Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 578-585.	1.0	28
48	Relationship between dialytic parameters and reviewer confirmed arrhythmias in hemodialysis patients in the monitoring in dialysis study. <i>BMC Nephrology</i> , 2019, 20, 80.	0.8	23
49	Kidney Recovery and Death in Critically Ill Patients With COVID-19 Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study. <i>American Journal of Kidney Diseases</i> , 2022, 79, 404-416.e1.	2.1	23
50	Comparative Utilization and Temporal Trends in Cardiac Stress Testing in U.S. Medicare Beneficiaries With and Without Chronic Kidney Disease. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1420-1426.	2.3	20
51	Location of acute coronary artery thromboses in patients with and without chronic kidney disease. <i>Kidney International</i> , 2009, 75, 80-87.	2.6	19
52	Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 810-822.	2.2	18
53	A Systematic Review of the Incidence of Arrhythmias in Hemodialysis Patients Undergoing Long-Term Monitoring With Implantable Loop Recorders. <i>Kidney International Reports</i> , 2021, 6, 56-65.	0.4	18
54	Echocardiographic parameters and renal outcomes in patients with preserved renal function, and mild- moderate CKD. <i>BMC Nephrology</i> , 2018, 19, 176.	0.8	16

#	ARTICLE	IF	CITATIONS
55	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 522-531.	2.1	15
56	Nephrology and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1137.	3.8	15
57	Accelerated Venovenous Hemofiltration as a Transitional Renal Replacement Therapy in the Intensive Care Unit. <i>American Journal of Nephrology</i> , 2020, 51, 318-326.	1.4	15
58	Comparative Effectiveness of Medical Therapy, Percutaneous Revascularization, and Surgical Coronary Revascularization in Cardiovascular Risk Subgroups of Patients With CKD: A Retrospective Cohort Study of Medicare Beneficiaries. <i>American Journal of Kidney Diseases</i> , 2019, 74, 463-473.	2.1	14
59	Early versus late initiation of renal replacement therapy in patients with acute kidney injury: a meta-analysis of randomised clinical trials. <i>Swiss Medical Weekly</i> , 2017, 147, w14507.	0.8	14
60	Association of Chronic Kidney Disease with Preserved Ejection Fraction Heart Failure Is Independent of Baseline Cardiac Function. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 1247-1258.	0.9	13
61	Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1369-1376.	0.4	13
62	Extracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney Injury. <i>Kidney International Reports</i> , 2018, 3, 1119-1127.	0.4	12
63	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391.	0.7	12
64	Allograft rejection and glomerular basement membrane antibodies in Alport's syndrome. <i>Journal of Nephrology</i> , 2004, 17, 431-5.	0.9	12
65	Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2578-2585.	0.4	11
66	You are what you eat: dietary salt intake and renin-angiotensin blockade in diabetic nephropathy. <i>Kidney International</i> , 2012, 82, 257-259.	2.6	11
67	Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease. <i>JAMA Network Open</i> , 2018, 1, e183874.	2.8	11
68	Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 757-764.	2.2	11
69	Obesity, inflammatory and thrombotic markers, and major clinical outcomes in critically ill patients with COVID-19 in the US. <i>Obesity</i> , 2021, 29, 1719-1730.	1.5	11
70	Acute Peritoneal Dialysis During the COVID-19 Pandemic at Bellevue Hospital in New York City. <i>Kidney360</i> , 2020, 1, 1345-1352.	0.9	11
71	Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden. <i>Fibrogenesis and Tissue Repair</i> , 2015, 8, 13.	3.4	9
72	Direct oral anticoagulants in chronic kidney disease: an update. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 489-496.	1.0	9

#	ARTICLE	IF	CITATIONS
73	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDESCENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.	2.2	9
74	An Exploratory Qualitative Study of Patient and Caregiver Perspectives of Ambulatory Kidney Palliative Care. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 1242-1249.	0.8	8
75	Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Stable Angina in Advanced CKD: A Decision Analysis. <i>American Journal of Kidney Diseases</i> , 2017, 69, 350-357.	2.1	7
76	Implantable Loop Recorder Monitoring and the Incidence of Previously Unrecognized Atrial Fibrillation in Patients on Hemodialysis. <i>Kidney International Reports</i> , 2022, 7, 189-199.	0.4	7
77	Utilization of Palliative Care for Patients with COVID-19 and Acute Kidney Injury during a COVID-19 Surge. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 342-349.	2.2	7
78	Outcomes with revascularization and medical therapy in patients with coronary disease and chronic kidney disease: A meta-analysis. <i>Atherosclerosis</i> , 2022, 351, 41-48.	0.4	7
79	Circulating Endoglin Concentration Is Not Elevated in Chronic Kidney Disease. <i>PLoS ONE</i> , 2011, 6, e23718.	1.1	6
80	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <sc>CREDESCENCE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.	2.2	6
81	CKD and Coronary Collateral Supply in Individuals Undergoing Coronary Angiography after Myocardial Infarction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1079-1086.	2.2	5
82	Angiographic characteristics of coronary arterial segments progressing to myocardial infarction in patients with and without chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 232-239.	0.7	5
83	Risks of Death and Graft Failure After Surgical Versus Percutaneous Coronary Revascularization in Renal Transplant Patients. <i>Journal of the American Heart Association</i> , 2013, 2, e003558.	1.6	5
84	The Effect of Bicarbonate Administration via Continuous Venovenous Hemofiltration on Acid-Base Parameters in Ventilated Patients. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	5
85	Oxalate Nephropathy in an Oxalobacter formigenes-“Negative Subject. <i>Kidney International Reports</i> , 2020, 5, 754-757.	0.4	5
86	Electrolyte Changes in Contemporary Hemodialysis: A Secondary Analysis of the Monitoring in Dialysis Study. <i>Kidney360</i> , 2021, 2, 695-707.	0.9	5
87	Outcomes among Hospitalized Chronic Kidney Disease Patients with COVID-19. <i>Kidney360</i> , 2021, 2, 1107-1114.	0.9	5
88	Patient Activation Measure in Dialysis Dependent Patients in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, , ASN.2021030315.	3.0	5
89	Obesity Related Glomerulopathy in Adolescent Women: The Effect of Body Surface Area. <i>Kidney360</i> , 2022, 3, 113-121.	0.9	5
90	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDESCENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Do Implantable Defibrillators Help Patients With CKD?. American Journal of Kidney Diseases, 2014, 64, 4-6.	2.1	4
92	Association of activated vitamin D use with myocardial fibrosis and capillary supply: results of an autopsy study. Renal Failure, 2015, 37, 1067-1069.	0.8	4
93	Serum glucose and phosphorus concentrations during continuous renal replacement therapy using commercial replacement solutions with or without phosphorus. Hemodialysis International, 2020, 24, 330-334.	0.4	4
94	The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. Kidney360, 2021, 2, 445-455.	0.9	3
95	All-Cause Mortality and Progression to End-Stage Kidney Disease Following Percutaneous Revascularization or Surgical Coronary Revascularization in Patients with CKD. Kidney International Reports, 2021, 6, 1580-1591.	0.4	3
96	Costâ€Effectiveness of Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease and Acute Coronary Syndromes in the US Medicare Program. Journal of the American Heart Association, 2021, 10, e019391.	1.6	3
97	Automated Determination of Left Ventricular Function Using Electrocardiogram Data in Patients on Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 1017-1025.	2.2	3
98	How is the Heart Best Protected in Chronic Dialysis Patients?. Seminars in Dialysis, 2014, 27, 325-328.	0.7	2
99	Spironolactone in Dialysis: Whatâ€™s Old Is New Again. American Journal of Kidney Diseases, 2016, 68, 512-514.	2.1	2
100	Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360, 2020, 1, 1380-1389.	0.9	2
101	Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stenting. Journal of Nephrology, 2006, 19, 764-70.	0.9	2
102	Cardiovascular Risk Prediction Scores in CKD: What Are We Missing?. Journal of the American Society of Nephrology: JASN, 2022, 33, 462-464.	3.0	2
103	Controlled Study of Decision-Making Algorithms for Kidney Replacement Therapy Initiation in Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 194-204.	2.2	2
104	Shades of Grey. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1107-1109.	2.2	1
105	Cardiovascular Issues Among Homeless People: An Issue that Needs Attention. Clinical Medicine Insights: Cardiology, 2020, 14, 117954682097503.	0.6	1
106	Relationship of aortic atherosclerosis to acute renal failure following cardiac surgery. Journal of Nephrology, 2006, 19, 628-33.	0.9	1
107	The Authors Reply. Kidney International, 2018, 94, 430-431.	2.6	0
108	Identification of ESRD in Cardiovascular Procedural Databases. Kidney International Reports, 2019, 4, 1477-1482.	0.4	0

#	ARTICLE	IF	CITATIONS
109	P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
110	P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
111	Mineralocorticoid Receptor Antagonists and Cardiovascular Health with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 843-845.	2.2	0
112	Cobalt alloy hip prostheses and new-onset heart failure in patients with and without chronic kidney disease. Clinical Nephrology, 2020, 94, 215-216.	0.4	0
113	Screening for Cardiovascular Disease in CKD: CON. Kidney360, 2022, 3, 1836-1838.	0.9	0